Pranav Sharma1, Rosa Djajadiningrat2, Kamran Zargar-Shoshtari1, Mario Catanzaro3, Yao Zhu4, Nicola Nicolai3, Simon Horenblas2, Philippe E Spiess5. 1. Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. 2. Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. 3. Department of Urology, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy. 4. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China. 5. Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL. Electronic address: philippe.spiess@moffitt.org.
Abstract
OBJECTIVES: We determined whether adjuvant chemotherapy (AC) would be associated with improved survival after lymph node dissection (LND) for patients with penile cancer (PeCa) who have positive pelvic lymph nodes (PPLNs). METHODS: We retrospectively identified patients across 4 centers with penile squamous cell carcinoma who underwent LND from 1978 to 2013 and were found to have PPLNs. Patients who received chemotherapy before surgery or in the presence of recurrent disease were excluded. Cox regression was used to evaluate the association of AC with overall survival (OS), which was estimated using the Kaplan-Meier method. Differences in OS were determined with the log-rank test. RESULTS: During the study period, 141 patients who underwent LND for PeCa had PPLNs, and 84 of them met inclusion criteria. Median number of PPLNs was 2 (interquartile range [IQR]: 4-7), with 10% of cases occurring bilaterally and 55% having pelvic extranodal extension. AC was used in 36 (43%) patients. Patients who received AC were younger (P = 0.014), had less-aggressive penile tumor pathology (P<0.01), were less likely to receive adjuvant radiation (P<0.01), had less bilateral inguinal disease (P = 0.019), and had more inguinal extranodal extension (P = 0.042). Median follow-up was 12.1 months. Estimated median OS was 21.7 months (IQR: 11.8-104) in patients who received AC vs. 10.1 (IQR: 5.6-48.1) in those who did not (P = 0.048). AC was independently associated with improved OS on multivariate analysis (hazard ratio: 0.40; 95% CI: 0.19-0.87; P = 0.021). CONCLUSIONS: AC is associated with improved OS in patients with PeCa who have PPLNs after LND. Prospective studies are needed to demonstrate causality.
OBJECTIVES: We determined whether adjuvant chemotherapy (AC) would be associated with improved survival after lymph node dissection (LND) for patients with penile cancer (PeCa) who have positive pelvic lymph nodes (PPLNs). METHODS: We retrospectively identified patients across 4 centers with penile squamous cell carcinoma who underwent LND from 1978 to 2013 and were found to have PPLNs. Patients who received chemotherapy before surgery or in the presence of recurrent disease were excluded. Cox regression was used to evaluate the association of AC with overall survival (OS), which was estimated using the Kaplan-Meier method. Differences in OS were determined with the log-rank test. RESULTS: During the study period, 141 patients who underwent LND for PeCa had PPLNs, and 84 of them met inclusion criteria. Median number of PPLNs was 2 (interquartile range [IQR]: 4-7), with 10% of cases occurring bilaterally and 55% having pelvic extranodal extension. AC was used in 36 (43%) patients. Patients who received AC were younger (P = 0.014), had less-aggressive penile tumor pathology (P<0.01), were less likely to receive adjuvant radiation (P<0.01), had less bilateral inguinal disease (P = 0.019), and had more inguinal extranodal extension (P = 0.042). Median follow-up was 12.1 months. Estimated median OS was 21.7 months (IQR: 11.8-104) in patients who received AC vs. 10.1 (IQR: 5.6-48.1) in those who did not (P = 0.048). AC was independently associated with improved OS on multivariate analysis (hazard ratio: 0.40; 95% CI: 0.19-0.87; P = 0.021). CONCLUSIONS: AC is associated with improved OS in patients with PeCa who have PPLNs after LND. Prospective studies are needed to demonstrate causality.
Authors: Dominic H Tang; Rosa Djajadiningrat; Gregory Diorio; Juan Chipollini; Zhenjun Ma; Braydon J Schaible; Mario Catanzaro; Dingwei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Peter A S Johnstone; Philippe E Spiess Journal: Urol Oncol Date: 2017-06-27 Impact factor: 3.498
Authors: Andrew T Lenis; Nicholas M Donin; David C Johnson; Izak Faiena; Amirali Salmasi; Alexandra Drakaki; Arie Belldegrun; Allan Pantuck; Karim Chamie Journal: J Urol Date: 2017-05-04 Impact factor: 7.450
Authors: Andrea Necchi; Gregory R Pond; Daniele Raggi; Sarah R Ottenhof; Rosa S Djajadiningrat; Simon Horenblas; Vincent Khoo; Oliver W Hakenberg; Desiree Draeger; Chris Protzel; Axel Heidenreich; Friederike Haidl; Bernie J Eigl; Lucia Nappi; Kazumasa Matsumoto; Ulka Vaishampayan; Michael E Woods; Roberto Salvioni; Nicola Nicolai; Mario Catanzaro; Patrizia Giannatempo; Daniel M Geynisman; Mirko Preto; Evanguelos Xylinas; Matthew I Milowsky; Sabino De Placido; Giuseppe Di Lorenzo; Guru Sonpavde Journal: Clin Genitourin Cancer Date: 2017-02-27 Impact factor: 2.872
Authors: Zhigang Yuan; Arash O Naghavi; Dominic Tang; Youngchul Kim; Kamran A Ahmed; Jasreman Dhillon; Anna R Giuliano; Philippe E Spiess; Peter A Johnstone Journal: World J Urol Date: 2018-03-27 Impact factor: 4.226
Authors: F A Distler; S Pahernik; G Gakis; G Hutterer; S Lebentrau; M Rink; P Nuhn; S Brookman-May; M Burger; C Gratzke; I Wolff; M May Journal: World J Urol Date: 2019-12-13 Impact factor: 4.226
Authors: Peter A S Johnstone; David Boulware; Rosa Djajadiningrat; Sarah Ottenhof; Andrea Necchi; Mario Catanzaro; Dingwei Ye; Yao Zhu; Nicola Nicolai; Simon Horenblas; Philippe E Spiess Journal: Eur Urol Focus Date: 2018-10-14